Aurora kinases in head and neck cancer

The Lancet Oncology

Volumn 14, Issue 10, 2013, Pages

  Mehra, Ranee ^a   Serebriiskii, Ilya G ^a   Burtness, Barbara ^a   Astsaturov, Igor ^a   Golemis, Erica A ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; ALISERTIB; AMG 900; AURORA A KINASE; AURORA B KINASE; AURORA KINASE INHIBITOR; BARASERTIB; CARBOPLATIN; CETUXIMAB; DANUSERTIB; DASATINIB; DOCETAXEL; ENMD 2076; EPIDERMAL GROWTH FACTOR RECEPTOR; GSK 1070916 A; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; PACLITAXEL; PAZOPANIB; PF 3814735; SEPANTRONIUM BROMIDE; TAK 733; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ANEUPLOIDY; APOPTOSIS; AURKA GENE; AURKB GENE; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; COLON CANCER; COLORECTAL CANCER; DISEASE ASSOCIATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; ESOPHAGUS CANCER; FATIGUE; GENE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC DATABASE; GENETIC TRANSCRIPTION; GENOMIC INSTABILITY; GENOMICS; HEAD AND NECK CANCER; HIGH THROUGHPUT SCREENING; HODGKIN DISEASE; HUMAN; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; SOMNOLENCE; SQUAMOUS CELL CARCINOMA; STOMACH CANCER;

CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; HEAD AND NECK NEOPLASMS; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; TRANSCRIPTOME;

EID: 84882931747     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70128-1     Document Type: Review

References (90)

1. Parkin DM, Bray F, Ferlay J, Pisani P Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Siegel R, Desantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012, 62:220-241.
3. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007, 356:1944-1956.
4. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011, 29:4294-4301.
5. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008, 100:261-269.
6. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010, 363:24-35.
7. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010, 28:4142-4148.
8. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008, 359:1116-1127.
9. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
10. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005, 23:5578-5587.
11. Glover DM, Leibowitz MH, McLean DA, Parry H Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell 1995, 81:95-105.
12. Palazzo RE, Vogel JM, Schnackenberg BJ, Hull DR, Wu X Centrosome maturation. Curr Top Dev Biol 2000, 49:449-470.
13. Mahen R, Venkitaraman AR Pattern formation in centrosome assembly. Curr Opin Cell Biol 2012, 24:14-23.
14. Seki A, Coppinger JA, Jang CY, Yates JR, Fang G Bora and the kinase aurora A cooperatively activate the kinase Plk1 and control mitotic entry. Science 2008, 320:1655-1658.
15. Macurek L, Lindqvist A, Lim D, et al. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature 2008, 455:119-123.
16. Chan EH, Santamaria A, Sillje HH, Nigg EA Plk1 regulates mitotic aurora A function through betaTrCP-dependent degradation of hBora. Chromosoma 2008, 117:457-469.
17. Dutertre S, Cazales M, Quaranta M, et al. Phosphorylation of CDC25B by aurora-A at the centrosome contributes to the G2-M transition. J Cell Sci 2004, 117:2523-2531.
18. Hauf S, Cole RW, LaTerra S, et al. The small molecule Hesperadin reveals a role for aurora kinase B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 2003, 161:281-294.
19. Carmena M, Earnshaw WC The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003, 4:842-854.
20. Kimmins S, Crosio C, Kotaja N, et al. Differential functions of the aurora-B and aurora-C kinases in mammalian spermatogenesis. Mol Endocrinol 2007, 21:726-739.
21. Nikonova AS, Astsaturov I, Serebriiskii IG, Dunbrack RL, Golemis EA Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci 2013, 70:661-687.
22. Lampson MA, Cheeseman IM Sensing centromere tension: aurora B and the regulation of kinetochore function. Trends Cell Biol 2011, 21:133-140.
23. Marumoto T, Zhang D, Saya H Aurora-A - a guardian of poles. Nat Rev Cancer 2005, 5:42-50.
24. Anand S, Penrhyn-Lowe S, Venkitaraman AR AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003, 3:51-62.
25. -/- cells. EMBO J 2002, 21:483-492.
26. Pugacheva EN, Golemis EA The focal adhesion scaffolding protein HEF1 regulates activation of the aurora-A and Nek2 kinases at the centrosome. Nat Cell Biol 2005, 7:937-946.
27. Pugacheva EN, Golemis EA HEF1-aurora A interactions: points of dialog between the cell cycle and cell attachment signaling networks. Cell Cycle 2006, 5:384-391.
28. Briassouli P, Chan F, Savage K, Reis-Filho JS, Linardopoulos S Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of IkappaBalpha. Cancer Res 2007, 67:1689-1695.
29. Lim KH, Brady DC, Kashatus DF, et al. Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA. Mol Cell Biol 2010, 30:508-523.
30. Katayama H, Ota T, Jisaki F, et al. Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst 1999, 91:1160-1162.
31. Sorrentino R, Libertini S, Pallante PL, et al. Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab 2005, 90:928-935.
32. Zeng WF, Navaratne K, Prayson RA, Weil RJ Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme. J Clin Pathol 2007, 60:218-221.
33. Erpolat OP, Gocun PU, Akmansu M, Karakus E, Akyol G High expression of nuclear survivin and aurora B predicts poor overall survival in patients with head and neck squamous cell cancer. Strahlenther Onkol 2012, 188:248-254.
34. Katayama H, Sasai K, Kawai H, et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 2004, 36:55-62.
35. Chen SS, Chang PC, Cheng YW, Tang FM, Lin YS Suppression of the STK15 oncogenic activity requires a transactivation-independent p53 function. EMBO J 2002, 21:4491-4499.
36. Gully CP, Velazquez-Torres G, Shin JH, et al. Aurora B kinase phosphorylates and instigates degradation of p53. Proc Natl Acad Sci USA 2012, 109:E1513-E1522.
37. Tatsuka M, Sato S, Kanda A, et al. Oncogenic role of nuclear accumulated aurora-A. Mol Carcinog 2009, 48:810-820.
38. Reiter R, Gais P, Jutting U, et al. Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res 2006, 12:5136-5141.
39. Zhang H, Chen X, Jin Y, Liu B, Zhou L Overexpression of aurora-A promotes laryngeal cancer progression by enhancing invasive ability and chromosomal instability. Eur Arch Otorhinolaryngol 2012, 269:607-614.
40. Mazumdar A, Henderson YC, El-Naggar AK, Sen S, Clayman GL Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head Neck 2009, 31:625-634.
41. Tatsuka M, Sato S, Kitajima S, et al. Overexpression of aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis. Oncogene 2005, 24:1122-1127.
42. Kitajima S, Kudo Y, Ogawa I, et al. Constitutive phosphorylation of aurora-A on ser51 induces its stabilization and consequent overexpression in cancer. PLoS One 2007, 2:e944.
43. Fidler C, Yang D, Zhu F, et al. Expression of aurora A and phospho-aurora-A is predictive of survival in patients with head and neck cancer. American Association for Cancer Research Annual Meeting; Chicago, IL, USA; March 31-April 4, 2012.
44. Moeder CB, Giltnane JM, Moulis SP, Rimm DL Quantitative, fluorescence-based in-situ assessment of protein expression. Methods Mol Biol 2009, 520:163-175.
45. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000, 92:709-720.
46. Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006, 24:736-747.
47. Weinberger PM, Yu Z, Haffty BG, et al. Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer. Clin Cancer Res 2004, 10:5684-5691.
48. Qi G, Ogawa I, Kudo Y, et al. Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer. Virchows Arch 2007, 450:297-302.
49. Bolton MA, Lan W, Powers SE, McCleland ML, Kuang J, Stukenberg PT Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. Mol Biol Cell 2002, 13:3064-3077.
50. Barrett T, Troup DB, Wilhite SE, et al. NCBI GEO: archive for functional genomics data sets-10 years on. Nucleic Acids Res 2011, 39:D1005-D1010.
51. Hruz T, Laule O, Szabo G, et al. Genevestigator v3: a reference expression database for the meta-analysis of transcriptomes. Adv Bioinformatics 2008, 2008:420747.
52. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012, 2:401-404.
53. Hennessey PT, Ochs MF, Mydlarz WW, et al. Promoter methylation in head and neck squamous cell carcinoma cell lines is significantly different than methylation in primary tumors and xenografts. PLoS One 2011, 6:e20584.
54. Lau AW, Fukushima H, Wei W The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis. Front Biosci 2012, 17:2197-2212.
55. Zhang H, Chen X, Liu B, Zhou L Effects of stable knockdown of aurora kinase A on proliferation, migration, chromosomal instability, and expression of focal adhesion kinase and matrix metalloproteinase-2 in HEp-2 cells. Mol Cell Biochem 2011, 357:95-106.
56. Chou CH, Yang NK, Liu TY, et al. Chromosome instability modulated by BMI1-AURKA signaling drives progression in head and neck cancer. Cancer Res 2013, 73:953-966.
57. Chakravarty A, Shinde V, Tabernero J, et al. Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of aurora A kinase. Cancer Res 2011, 71:675-685.
58. Cohen RB, Jones SF, Aggarwal C, et al. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res 2009, 15:6694-6701.
59. Dees EC, Cohen RB, von Mehren M, et al. Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res 2012, 18:4775-4784.
60. Dees EC, Infante JR, Cohen RB, et al. Phase 1 study of MLN8054, a selective inhibitor of aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011, 67:945-954.
61. Jani JP, Arcari J, Bernardo V, et al. PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Mol Cancer Ther 2010, 9:883-894.
62. Hardwicke MA, Oleykowski CA, Plant R, et al. GSK1070916, a potent aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther 2009, 8:1808-1817.
63. Astsaturov I, Ratushny V, Sukhanova A, et al. Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci Signal 2010, 3:ra67.
64. Lucas JT, Salimath BP, Slomiany MG, Rosenzweig SA Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent. Oncogene 2010, 29:4449-4459.
65. Tikhmyanova N, Little JL, Golemis EA CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci 2010, 67:1025-1048.
66. Hoellein A, Pickhard A, von Keitz F, et al. Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck. Oncotarget 2011, 2:599-609.
67. Collins S, Blair D, Zarycki J, et al. A rationale for combining the targeted investigational agents TAK-733, a MEK1/2 inhibitor, with alisertib (MLN8237), an aurora A kinase inhibitor, for cancer therapy. Cancer Res 2012, 6(suppl):3738.
68. Isham CR, Bossou AR, Negron V, et al. Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer. Sci Transl Med 2012, 5:166ra3.
69. Bible KC, Suman VJ, Menefee ME, et al. A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab 2012, 97:3179-3184.
70. VanderPorten EC, Taverna P, Hogan JN, Ballinger MD, Flanagan WM, Fucini RV The aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol Cancer Ther 2009, 8:930-939.
71. Sehdev V, Katsha A, Ecsedy J, Zaika A, Belkhiri A, El-Rifai W The combination of alisertib, an investigational aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas. Cancer 2013, 119:904-914.
72. Mahadevan D, Stejskal A, Cooke LS, et al. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma. Clin Cancer Res 2012, 18:2210-2219.
73. Minton SE, LoRusso P, Lockhart AC, et al. A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2010, 28(suppl):e13026.
74. Singh MK, Izumchenko E, Klein-Szanto AJ, Egleston BL, Wolfson M, Golemis EA Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9. Cancer Res 2010, 70:8907-8916.
75. Tikhmyanova N, Golemis EA NEDD9 and BCAR1 negatively regulate E-cadherin membrane localization, and promote E-cadherin degradation. PLoS One 2011, 6:e22102.
76. Ratushny V, Pathak HB, Beeharry N, et al. Dual inhibition of SRC and aurora kinases induces postmitotic attachment defects and cell death. Oncogene 2012, 31:1217-1227.
77. Wheeler DL, Iida M, Kruser TJ, et al. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther 2009, 8:696-703.
78. Pugacheva EN, Jablonski SA, Hartman TR, Henske EP, Golemis EA HEF1-dependent aurora A activation induces disassembly of the primary cilium. Cell 2007, 129:1351-1363.
79. Jackman M, Lindon C, Nigg EA, Pines J Active cyclin B1-Cdk1 first appears on centrosomes in prophase. Nat Cell Biol 2003, 5:143-148.
80. Zhang XH, Rao M, Loprieato JA, et al. Aurora A, aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer. Cancer Biol Ther 2008, 7:1388-1397.
81. Kretzner L, Scuto A, Dino PM, et al. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Res 2011, 71:3912-3920.
82. Qi G, Kudo Y, Ando T, et al. Nuclear survivin expression is correlated with malignant behaviors of head and neck cancer together with aurora-B. Oral Oncol 2010, 46:263-270.
83. Carpinelli P, Moll J Aurora kinase inhibitors: identification and preclinical validation of their biomarkers. Expert Opin Ther Targets 2008, 12:69-80.
84. Licitra L, Storkel S, Kerr KM, et al. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer 2013, 49:1161-1168.
85. Arkenau HT, Plummer R, Molife LR, et al. A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Ann Oncol 2012, 23:1307-1313.
86. Hsu JY, Sun ZW, Li X, et al. Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes. Cell 2000, 102:279-291.
87. Schoffski P, Jones SF, Dumez H, et al. Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. Eur J Cancer 2011, 47:2256-2264.
88. Hayashi MT, Cesare AJ, Fitzpatrick JA, Lazzerini-Denchi E, Karlseder J A telomere-dependent DNA damage checkpoint induced by prolonged mitotic arrest. Nat Struct Mol Biol 2012, 19:387-394.
89. Bagnyukova TV, Serebriiskii IG, Zhou Y, Hopper-Borge EA, Golemis EA, Astsaturov I Chemotherapy and signaling: how can targeted therapies supercharge cytotoxic agents?. Cancer Biol Ther 2010, 10:839-853.
90. Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011, 29:2011-2019.